Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck's (MRK) diabetes drug Janumet. "The Biden-Harris ...

Jonsbo has recently announced the launch of two ultra-compact Mini-ITX cases ... resulting in a compact volume of only 4.54 liters. Despite their small size, they are engineered to support ...

Novo Nordisk A/S today announced 2024 earnings ... If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Novo Nordisk (NVO) reported better-than-expected ... Shares of the Danish drugmaker rose ~4% in European trading, while Eli Lilly (LLY), its main rival in the obesity market, added ~2% in the ...

Despite the company’s enthusiasm, questions remain about how Novo's latest numbers can move the needle in a competitive market. The company's stock price decline of 4% on Friday seems to ...

Novo Nordisk has an Earnings ESP of -1.42% and a Zacks Rank #4 (Sell) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. NVO operates under two segments — Diabetes ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. On Wednesday, Novo Nordisk A/S NVO ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...